Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
6/15/2026, 12:00:00 AM
Positive Phase 3 trial results for Jaypirca in combination with venetoclax and rituximab for CLL treatment showing 45% risk reduction expected on 2026-06-15; high impact estimated due to significant clinical efficacy.
Korean Translation
2026-06-15 만성 림프구성 백혈병(CLL) 치료를 위한 제이피르카 병용 요법의 3상 임상시험에서 45% 위험 감소 결과 발표가 예상됨.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day scheduled in New York City to provide updates on company strategy, growth initiatives, and long-term financial plan. Low impact is anticipated as this is a routine strategy update scheduled
9/16/2026, 12:00:00 AM
Broadcom Inc (AVGO) · Earnings Release
Q3 2026 earnings release and conference call on September 3, 2026, for which the importance is estimated as High based on typical market reaction, scheduled.
9/3/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
Marvell is expected to announce its Q2 fiscal 2027 earnings on or around August 27, 2026. This event is expected to have a price impact of at least 5% based on historical earnings volatility expected
8/27/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart is scheduled to release its Q2 FY2027 earnings on August 20, 2026, before the market opens; a price impact of approximately 5% is estimated based on historical earnings volatility, scheduled.
8/20/2026, 12:00:00 AM
Applied Materials Inc (AMAT) · Other
A quarterly cash dividend of $0.53 per share was declared, with the ex-dividend date set for August 20, 2026.
8/20/2026, 12:00:00 AM
Keysight Technologies Inc (KEYS) · Earnings Release
Q3 2026 earnings release on August 18, 2026, with company revenue forecast of $1.730-$1.750 billion and non-GAAP EPS of $2.43-$2.49 (High importance estimated due to typical price volatility during earnings season) scheduled.
8/18/2026, 12:00:00 AM